Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
yes i think so ..though i need to check Timbo on the other board seems to think so : i quote : "Yes, that is my understanding, they get a fixed share of all payments and they contribute a fixed share of future development costs. Numis estimate Ergomed's share of Lorediplon at 10% (uncapped)" I have not seen the details of the contact with Ferrer and scoured through the regulatory announcement but it is short on details regarding the terms ..
Excellent - I guess a share of any upfront and milestone payments too?
yes happy to have put my toe in at a good timing .. from the last presentation they claim to have "double digits of Lorediplon and high single digits of Zoptrex
Excellent news:- - Ergomed announces positive Phase II top-line results of co-development partner Ferrer's Lorediplon - Both 5 and 10mg Lorediplon met the primary endpoint with high statistical significance - Key secondary endpoints were met - Under the terms of the co-development partnership with Ferrer, Ergomed will receive a share of the revenue received from the commercialisation of the drug
To be honest, I bought into Ergomed some time ago, mainly because it was a revenue generating CRO, I liked the story and it sort of nicely balanced my portfolio within the bio sector. I also liked the fact that it appeared to be very much under the radar - completely empty bb so no hype. Since then, I've pretty much shoved them in the bottom drawer and not paid too much attention. So the strong rise over the past 3 months has been a very pleasant surprise and am now trying to brush up on my original research to get up to speed again.
Thanks Boom .Ergo was on my "watching "list, but i took my eyes off the ball as i was busy on non investment matters..Furthermore i have been loathe to reduce my largest holding as i still think it will produce multi baggers returns in the not too distant future ..But the latest RNS on Ergo made me focus again ..initially i was put off by the 384 death . But those patients may have been grateful to have been able to prolong their life somewhat ( at no cost ) . It reminded me my first appraisal of this stock : good growth in earnings , allowing them to take stakes in he most promising drugs for which they manage the trial .. so great potential upside , and downside cushioned by the bread and butter business .. 2017 /2018 seem to have good potential inflection points on that score , whilst the growth of the core business is likely to continue through acquisition of pharmacology companies ...
Sorry, have only just seen your post from last night. Yes, from Ergomed's point of view the trial seems to have gone well. Usually you are keen to see these trials draw to an end but this is one that you wish would drag on and on, given that it was designed to end after the death of 384 patients. The comments from Aeterna Zentaris do sound very hopeful. They've already signed several licensing agreements (4, I think) and of course Ergomed will share in any milestone payments that may be triggered by a successful trial/NDA/marketing approval. Think results for Ferrer's insomnia treatment lorediplon are due either this or next week too.
If you would like to listen to a recording of the presentation it is now available at: https://www.youtube.com/watch?v=Hm7n9xXCMFY
I am new to this stock , so please bear with me I am surprised to see no comment on today's RNS on the completion of Zoptrex P3 trial a drug on which i believe we are entitled to 18% of revenues I appreciate that we have to wait for full results to be analysed and revealed in April but the wording of the RNS seems to be upbeat Am i barking up the wrong tree ?
Blimey - yes. Tend not to check this stock on a day to day basis and just happened to have a look following the RNS.
ERGO going really well today, even following the recent healthy upticks....full ask of 213p paid just now. Something must have kicked off ERGO for a further run.....the most recent started 1313 hrs.
Yes, most definitely under the radar. SP has been steadily rising since November and the trading statement issued on 17th Jan seems to have given more momentum to the rise. SP has quietly moved almost unnoticed to an all time high.
It's so quiet here, against the background of the soaring ERGO sp, I can't but feel that many folks here could benefit from checking out the company. For starters, current target prices are around 265p with much more to come from this dynamic business which only came to market as recently as mid-2014. gl!
If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of January. Also appearing will be the management of Kromek and Realm Therapeutics. To learn more about the forum and to register for free please follow this link: https://www.eventbrite.co.uk/e/equity-development-investor-forum-january-2017-tickets-30349576400 Thanks, The Equity Development team
Positive update this morning. · Unaudited 2016 revenues expected to be approximately £38 million - up 26% from £30.2 million in 2015 · Approximately £42 million of contracts were won in 2016 up 50% from £28 million in 2015 · Exited year with backlog of contracted future work of approximately £70 million http://www.investegate.co.uk/ergomed-plc--ergo-/rns/trading-statement/201701170700072961U/
Steady rise continues. Wish the 3 month chart for all stocks in my portfolio looked like this. Stephen Stamp, Chief Finance Officer for Ergomed will be presenting at an Equity Development Investment Forum on 25th Jan in London. More importantly, Andrew Mackie is presenting at the invitation only JP Morgan Healthcare Conference in San Francisco next week.
Clinical trial results from 2 of Ergomed's partners are due very soon. The first is phase IIa trial results for Ferrer's insomnia treatment lorediplon and the second is Aeterna Zentaris' Zoptrex for endometrial cancer. Zoptrex is the big one - it's a phase III trial and if the results are positive a new drug application will be filed in H1 2017 (with the benefit of FDA Special Protocol Assessment). Aeterna Zentaris has already signed 4 licensing agreements for Zoptrex and a successful phase III will presumably trigger milestone payments. Ergomed will be entitled to a share of any payments and royalties if the NDA is approved.
.....paid today - still only a little above half of the 267p - 271p targets for this share.
Great share for 2017 organic growth & acquisitions & a great Chairman who has already built $billion companies.
........of of European PharmInvent Services s.r.o. a European pharmacovigilance and regulatory services business. Initial price of £4.1 m and further payments of up to a total of £2.7 m subject to the achievement of EBITDA targets for 2016, 2017 and 2018. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/acquisition-of-pharminvent/201611290700083466Q/
Ergomed attending Bio Europe over the next couple of days http://www.ebdgroup.com/bioeurope/core/participating-companies.php?_ga=1.231295071.1507294036.1475222496
Interesting RNS and seems to be a pattern developing here. Another Swedish company with links to Karolinska Dev. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/co-development-agreement-with-asarina-ab/201611010700069182N/
Karolinska have decided to continue with development of Dilaforette with a change of name to Modus Therapeutics and an IPO - I guess onto Nasdaq, Stockholm. Good stuff. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-notes-news-from-co-development-partner/201610240700082180N/
Proactive Investors is here: http://tinyurl.com/hkl2g4b
We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around 30mins followed by Q+A. If you would like to join please register for free at: https://attendee.gotowebinar.com/register/7094329775007801604 The Equity Development team